- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Cystic fibrosis
- Meeting Date: July 2023
- Public Summary Document (PSD) July 2023 PBAC Meeting - (PDF 689KB)
- Public Summary Document (PSD) July 2023 PBAC Meeting - (Word 158KB)
Lumacaftor with ivacaftor – July 2023
Lumacaftor with ivacaftor: Sachet containing granules, lumacaftor 150 mg with ivacaftor 188 mg, Sachet containing granules, lumacaftor 75 mg with ivacaftor 94 mg, Sachet containing granules, lumacaftor 100 mg with ivacaftor 125 mg; Orkambi®
Last updated
27 October 2023
